Format

Send to

Choose Destination
Urology. 2008 Oct;72(4):813-6. doi: 10.1016/j.urology.2008.04.069. Epub 2008 Aug 9.

Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study.

Author information

1
Urology Research Center, Razi Hospital, Guilan University of Medical Sciences, Rasht, Islamic Republic of Iran.

Abstract

OBJECTIVES:

Nocturia is a well-recognized symptom of benign prostatic hyperplasia (BPH), which is commonly treated by alpha(1)-blockers and/or 5alpha-reductase inhibitors. However, the effectiveness of these drugs for nocturia has been reported to be only 25%-39%. The aim of this study was to investigate the efficacy of celecoxib, a cyclooxygenase-2 inhibitor, in the treatment of patients with BPH complaining of nocturia.

METHODS:

This was a prospective, randomized, double-blind, placebo-controlled study. A total of 80 men with lower urinary tract symptoms and BPH were entered into the study and were randomized to receive celecoxib, 100 mg at 9 pm vs placebo for 1 month. The inclusion criteria also included a total International Prostate Symptom Score >8 and complaints of >or=2 voids nightly. The efficacy and safety of the treatment were assessed by changes in the urinary flow and symptoms between baseline and 1 month of follow-up.

RESULTS:

In the celecoxib group (n = 40), the mean nocturnal frequency (+/-SD) decreased from 5.17 +/- 2.1 to 2.5 +/- 1.9 (P < .0001), and the mean International Prostate Symptom Score (+/-SD) decreased from 18.2 +/- 3.4 to 15.5 +/- 4.2 (P < .0001). In the control group (n = 40), the mean nocturnal frequency (+/-SD) decreased from 5.30 +/- 2.4 to 5.12 +/- 1.9 (P > .05), and the mean International Prostate Symptom Score (+/-SD) decreased from 18.4 +/- 3.1 to 18 +/- 3.9 (P > .05). A statistically significant difference was found between the 2 groups (P < .0001). No statistically significant differences were found in the changes in the peak flow rate between the celecoxib and control groups or in celecoxib group between baseline and 1 month (P > .05). No significant side effects were reported.

CONCLUSIONS:

Celecoxib is effective in the treatment of patients with BPH complaining of refractory nocturia. Our results suggest a novel treatment option for this common condition.

PMID:
18692876
DOI:
10.1016/j.urology.2008.04.069
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center